See more : Wm Morrison Supermarkets PLC (MRW.L) Income Statement Analysis – Financial Results
Complete financial analysis of Panbela Therapeutics, Inc. (PBLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Panbela Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- XinJiang GuoTong Pipeline CO.,Ltd (002205.SZ) Income Statement Analysis – Financial Results
- Shandong Fengxiang Co., Ltd (9977.HK) Income Statement Analysis – Financial Results
- Guangdong Lifestrong Pharmacy Co., Ltd. (301111.SZ) Income Statement Analysis – Financial Results
- Clipper Realty Inc. (CLPR) Income Statement Analysis – Financial Results
- Mechema Chemicals International Corp. (4721.TWO) Income Statement Analysis – Financial Results
Panbela Therapeutics, Inc. (PBLA)
About Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36M | 973.81K | 1.23M | 699.76K |
| Cost of Revenue | 25.65M | 35.73M | 10.01M | 5.75M | 4.32M | 3.89M | 6.02M | 5.17M | 5.44M | 595.15K | 558.47K | 691.80K | 550.54K |
| Gross Profit | -25.65M | -35.73M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | 761.84K | 415.35K | 540.90K | 149.21K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 56.14% | 42.65% | 43.88% | 21.32% |
| Research & Development | 20.61M | 28.05M | 5.42M | 2.51M | 2.35M | 1.78M | 2.59M | 2.50M | 2.85M | 2.37K | 279.79K | 0.00 | 0.00 |
| General & Administrative | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.81M | 837.24K | 329.88K | 258.10K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -217.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.59M | 837.24K | 329.88K | 258.10K | 253.72K |
| Other Expenses | 0.00 | -682.00K | -602.00K | 605.00K | -99.00K | -508.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 253.72K |
| Operating Expenses | 25.65M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 837.24K | 609.67K | 258.10K | 253.72K |
| Cost & Expenses | 51.29M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 1.43M | 1.17M | 949.90K | 804.26K |
| Interest Income | 123.00K | 14.00K | 1.00K | 17.00 | 2.19K | 0.00 | 1.00K | 2.00K | 8.00K | 4.00K | 18.41K | 0.00 | 0.00 |
| Interest Expense | -317.00K | 288.00K | 11.00K | 17.00K | 2.19M | 1.81M | 1.62M | 180.00K | 183.00K | 35.53K | 35.89K | 36.14K | 34.27K |
| Depreciation & Amortization | 0.00 | 16.36K | 10.01K | 5.75K | 4.32K | 3.89K | 6.02K | 5.17K | 8.00K | 9.58K | 8.79K | 5.64K | 3.10K |
| EBITDA | -51.29M | -34.76M | -10.61M | -5.15M | -4.42M | -1.76M | -6.02M | -5.17M | -5.12M | -75.40K | -194.32K | 289.44K | -101.40K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4.56% | -17.16% | 23.40% | -14.49% |
| Operating Income | -51.29M | -34.09M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | -75.40K | -194.32K | 282.80K | -104.50K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.56% | -19.95% | 22.94% | -14.93% |
| Total Other Income/Expenses | 25.85M | -956.00K | -613.00K | 691.00K | -2.29M | -2.27M | -4.89M | -285.00K | -564.00K | -31.53K | -17.48K | -35.14K | -33.69K |
| Income Before Tax | -25.45M | -35.05M | -10.62M | -5.06M | -6.62M | -6.16M | -10.91M | -5.45M | -5.68M | -106.92K | -211.80K | 247.66K | -138.20K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.88% | -21.75% | 20.09% | -19.75% |
| Income Tax Expense | -186.00K | -116.00K | -488.00K | -295.00K | -415.00K | -254.00K | -536.00K | -341.00K | -756.00K | 121.00 | 220.00 | 284.00 | 115.00 |
| Net Income | -25.26M | -34.93M | -10.14M | -4.77M | -6.20M | -5.91M | -10.37M | -5.11M | -4.93M | -107.04K | -212.02K | 247.38K | -138.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.89% | -21.77% | 20.07% | -19.77% |
| EPS | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| EPS Diluted | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| Weighted Avg Shares Out | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
| Weighted Avg Shares Out (Dil) | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2021 ASCO Annual Meeting
MINNEAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced the presentation of interim clinical data from its Phase 1b combination...
Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q1 2021 Results - Earnings Call Transcript
Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q1 2021 Results - Earnings Call Transcript
Panbela Provides Business Update and Reports Q1 2021 Financial Results
MINNEAPOLIS, May 12, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today provides a business update and reports financial results for the quarter ended...
Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting
MINNEAPOLIS, April 06, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been...
Corrected: Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results
MINNEAPOLIS, March 26, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), is re-issuing this press release solely to correct an inadvertent decimal error in the net loss per share reported in the discussion under the heading “Fourth Quarter ended...
Panbela Provides Business Update and Reports Q4 and FY 2020 Financial Results
MINNEAPOLIS, March 25, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business update and reports financial results for the quarter and...
Panbela Schedules Conference Call on March 25, 2021 to Report 2020 Fourth Quarter Financial Results
MINNEAPOLIS, March 17, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will host a conference call on March 25, 2021...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Panbela Therapeutics Inc. - PBLA
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Panbela Therapeutics Inc. ("Panbela" or the "Company") (NASDAQ: PBLA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Panbela Announces Research Agreement with Johns Hopkins University School of Medicine
MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a research agreement with the Johns Hopkins University School of Medicine....
Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.
MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective...
Source: https://incomestatements.info
Category: Stock Reports